Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial
-
Published:2021-02
Issue:
Volume:144
Page:351-359
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
R. Ferreira ArlindoORCID,
Ferreira SofiaORCID,
Lambertini MatteoORCID,
Maurer Christian,
Martel SamuelORCID,
Costa Luis,
Ponde NoamORCID,
de Azambuja EvandroORCID
Subject
Cancer Research,Oncology
Reference24 articles.
1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Canc,2015
2. Optimal treatment of early stage HER2-positive breast cancer;Pernas;Cancer,2018
3. HER2-positive advanced breast cancer treatment in 2020;Cesca;Cancer Treat Rev,2020
4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020
5. Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer;Von Minckwitz;N Engl J Med,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献